liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
In Vitro Metabolite Profiling of ADB-FUBINACA, A New Synthetic Cannabinoid
NIDA, MD 21224 USA.
NIDA, MD 21224 USA.
Linköping University, Department of Medical and Health Sciences, Division of Drug Research. Linköping University, Faculty of Medicine and Health Sciences. NIDA, MD 21224 USA; National Board Forens Med, Linkoping, Sweden.
NIDA, MD 21224 USA.
Show others and affiliations
2017 (English)In: Current Neuropharmacology, ISSN 1570-159X, E-ISSN 1875-6190, Vol. 15, no 5, 682-691 p.Article in journal (Refereed) Published
Abstract [en]

Background: Metabolite profiling of novel psychoactive substances (NPS) is critical for documenting drug consumption. N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1-Hindazole-3-carboxamide (ADB-FUBINACA) is an emerging synthetic cannabinoid whose toxicological and metabolic data are currently unavailable. Methods: We aimed to determine optimal markers for identifying ADB-FUBINACA intake. Metabolic stability was evaluated with human liver microsome incubations. Metabolites were identified after 1 and 3 h incubation with pooled human hepatocytes, liquid chromatography-high resolution mass spectrometry in positive-ion mode (5600(+) TripleTOF (R), Sciex) and several data mining approaches (MetabolitePilot (TM), Sciex). Results: Metabolite separation was achieved on an Ultra Biphenyl column (Restek (R)); full-scan TOF-MS and information-dependent acquisition MS/MS data were acquired. ADB-FUBINACA microsomal half-life was 39.7 min, with a predicted hepatic clearance of 9.0 mL/min/kg and a 0.5 extraction ratio (intermediate-clearance drug). Twenty-three metabolites were identified. Major metabolic pathways were alkyl and indazole hydroxylation, terminal amide hydrolysis, subsequent glucuronide conjugations, and dehydrogenation. Conclusion: We recommend ADB-FUBINACA hydroxyalkyl, hydroxydehydroalkyl and hydroxylindazole metabolites as ADB-FUBINACA intake markers. N-dealkylated metabolites are not specific ADB-FUBINACA metabolites and should not be used as definitive markers of consumption. This is the first ADB-FUBINACA in vitro metabolism study; in vivo experiments enabling pharmacokinetic and pharmacodynamics studies or urine from authentic clinical/forensic cases are needed to confirm our results.

Place, publisher, year, edition, pages
BENTHAM SCIENCE PUBL LTD , 2017. Vol. 15, no 5, 682-691 p.
Keyword [en]
ADB-FUBINACA; synthetic cannabinoid; novel psychoactive substances; metabolism; hepatocytes; LC-HRMS
National Category
Pharmaceutical Sciences
Identifiers
URN: urn:nbn:se:liu:diva-139310DOI: 10.2174/1570159X15666161108123419ISI: 000403639600004OAI: oai:DiVA.org:liu-139310DiVA: diva2:1120945
Note

Funding Agencies|Intramural Research Program of the National Institute on Drug Abuse, National Institutes of Health

Available from: 2017-07-07 Created: 2017-07-07 Last updated: 2017-07-07

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Wohlfarth, Ariane
By organisation
Division of Drug ResearchFaculty of Medicine and Health Sciences
In the same journal
Current Neuropharmacology
Pharmaceutical Sciences

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 91 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf